A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®

AAPS Journal - United States
doi 10.1208/s12248-019-0332-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody–Induced Tumor Cell Killing by Effector CD8+ T Cells

Journal of Immunology
AllergyImmunology
2019English

A Novel Bispecific Single-Chain Antibody for ADAM17 and CD3 Induces T-Cell-Mediated Lysis of Prostate Cancer Cells

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2012English

Development of PF-06671008, a Highly Potent Anti-P-Cadherin/Anti-Cd3 Bispecific DART Molecule With Extended Half-Life for the Treatment of Cancer

Antibodies
Drug DiscoveryAllergyImmunology
2016English

Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition

Journal of Immunology
AllergyImmunology
2007English

An Anti–glypican 3/Cd3 Bispecific T Cell–redirecting Antibody for Treatment of Solid Tumors

Science Translational Medicine
Medicine
2017English

A Bispecific Diabody Directed Against Prostate-Specific Membrane Antigen and CD3 Induces T-Cell Mediated Lysis of Prostate Cancer Cells

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2007English

A Novel GUCY2C-CD3 T Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers

Clinical Cancer Research
Cancer ResearchOncology
2020English

Novel Human Bispecific Aptamer–Antibody Conjugates for Efficient Cancer Cell Killing

Cancers
Cancer ResearchOncology
2019English

Cancer Vaccines: The Molecular Basis for T Cell Killing of Tumor Cells

Oncologist
Cancer ResearchMedicineOncology
1997English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy